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Abstract
Background: Current guidelines recommend metformin as the first-line agent therapy for the
management of Type 2 Diabetes (T2D) when diet and exercise are insufficient. When
monotherapy with metformin is intolerant or contraindicated, or not sufficiently effective to
reach the glycated hemoglobin (HbA1c) target, a second anti-diabetic agent as an alternative or
add-therapy to metformin is recommended by all guidelines. The quality improvement project
was initiated in the fall semester with a 10-day reflective practice log to assess my current
practice. A review of the clinical practice log allowed for evaluation of my current practice and
identify three opportunities to improve my practice. I developed three potential PICOT questions
and selected one for the QI project with the guidance of my Doctor of Nursing Practice (DNP)
chairperson. I performed a literature review in search of the best evidence-based intervention to
improve my practice. My current practice is metformin 500-1000mg twice daily as a first line
treatment for T2DM. The new evidence-based intervention that I found in the literature review
was to initiate empagliflozin 10-25mg once daily as the first line treatment or as add-on therapy
to metformin in adults 18 to 78 years of age with uncontrolled T2DM. The evidenced based QI
proposal was presented to the Internal Review Board (IRB) at The University of Texas at El Paso
(UTEP) and my worksite manager. An Approval letter was obtained from the IRB at UTEP and
work site manager before initiation of the QI project. The evidence-based QI project was
implemented for six weeks in the Spring semester.
Purpose: This Quality Improvement (QI) project aims to use a sodium-glucose cotransporter 2
(SGLT2) inhibitor alone or in combination with other agents to improve glycemic control in
patients 18 to 78 years of age with uncontrolled T2DM (HbA1c >7%) within 4 weeks.
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Methods: The Plan-Do-Study-Act (PDSA) method of quality improvement was used in this
project. Baseline HbA1c levels were recorded at the first visit before initiating the intervention.
Post-intervention HbA1c levels were recorded two weeks after initiating the intervention to
assess its efficacy and tolerance of the new medication. Blood pressure and weight were
recorded on the first visit and after initiating intervention.
Intervention: The SGLT2 inhibitor, empagliflozin was selected as first-line therapy for patients
with new-onset T2DM. Empagliflozin was added as a combination treatment to the drug
regimens of patients who presented with T2DM that was not adequately controlled by
metformin. Inclusion criteria were (1) all patients 18–79 years of age who were (2) newly
diagnosed or presenting with uncontrolled T2DM (HbA1c >7%). Kurt Lewin’s three-step model
was used as the translational theoretic framework for this project. The steps included (1)
Unfreeze (i.e., acknowledging that a change is needed); (2) Change (i.e., initiate treatment with
an SGLT2 inhibitor, and (3) Refreeze (i.e., make the change permanent and continue the patient
on this drug).
Results: Nineteen patients between the ages of 23–78 years old (18 females and one male) were
identified in the QI project. The average reduction in HbA1c levels was 0.21%. Thus, the results
of this project suggested an overall trend toward improvement of glycemic control.
Conclusion: Empagliflozin provided as monotherapy or as an add-on to metformin was effective
at reducing HbA1c to improve glycemic control. Patients treated with empagliflozin also
responded with reduced systolic blood pressure and weight loss.
Keywords: First-line treatment, Type 2 Diabetes, Glycemic control, Monotherapy,
Combination therapy, and Sodium-glucose cotransporter-2 inhibitor
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Empagliflozin and/or Metformin: A Combination Approach for Uncontrolled
Type 2 Diabetes
Increased emphasis has been placed on glycemic management in response to the rising
prevalence of type 2 diabetes mellitus (T2DM) in the United States. T2DM is a chronic
progressive disease associated with severe complications that include cardiovascular disease,
stroke, amputation, end-stage kidney disease, blindness, and premature death (American
Diabetes Association, 2020). The United States Centers for Disease Control and Prevention
(CDC) estimates that over 34.2 million people are living with diabetes in the United States alone;
90–95% of these individuals have been diagnosed with T2DM (Rowley et al., 2017). With more
than 4000 new cases of diabetes are diagnosed each day, the CDC predicts that the number of
people living with diabetes may reach ~55 million (Rowley et al., 2017). The resources needed
to provide adequate care for all patients with T2DM place a considerable economic burden on
healthcare systems that may already be overwhelmed.
Effective clinical management of type 2 diabetes mellitus (T2DM) requires an optimized
treatment plan to ensure adequate glycemic control and reduce the incidence of diabetic
complications. Because of the progressive nature of T2DM, standard first-line treatment with
metformin alone is frequently insufficient to achieve glycemic control. In these cases, additional
agents are required. The American Association of Clinical Endocrinology Consensus Statement
(Garber et al., 2020) recommends the addition of other oral agents to the standard metformin
regimen in patients who do not achieve target levels of glycated hemoglobin (HbA1c) after
approximately three months of monotherapy or an increase of HbA1c >1.5 %. There are
currently many new oral agents available for patients with newly-diagnosed or uncontrolled
T2DM. In addition to metformin, which is a biguanide, other non-insulin-based
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pharmacotherapies include sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl
peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists,
thiazolidinediones, (TZD), and sulfonylureas. The antihyperglycemic actions of these drugs are
mediated by a variety of distinct molecular mechanisms.
Problem Description
Ben Archer Health Center is a federally qualified health center located in the rural town
of Las Cruces, New Mexico that provides primary care to children and adults of all ages. The
current practice that was ineffective was Metformin 500-1000mg twice a day as initial treatment
for uncontrolled T2DM. The new evidence-based intervention produced by the literature review
was to initiate empagliflozin 10-25mg once daily as a first-line treatment or as an add-on therapy
to metformin in adults 18 to 78 years of age.
Available Knowledge
The American Diabetes Association (ADA) recommends the management of T2DM with
one of six commonly-used antihyperglycemic agents (AHAs), including (1) sulfonylureas; (2)
thiazolidinediones; (3) DPP4 inhibitors; (4) SGLT2 inhibitors; (5) GLP1 receptor agonists; or (6)
basal insulin analogs. These agents can be provided as add-on therapy when the individualized
HbA1c target level is not reached after approximately three months of treatment with metformin
alone. The ADA standards of care do not provide any specific recommendations regarding the
selection of a drug to be used in a dual-therapy regimen. Instead, their guidelines suggest that
drug selection can be based on patient preferences, risk of developing hypoglycemia, side effect
profile, and cost, among other patient and disease characteristics (American Diabetes
Association, 2020).
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The SGLT2 inhibitor, empagliflozin, reduces blood glucose levels in patients with
T2DM. Drugs of this class (also known as glucoretics) have a unique mechanism of action and
are among the most recently approved AHAs. The insulin-independent antihyperglycemic effects
of SGLT2 inhibitors are mediated by their capacity to suppress glucose reabsorption in the renal
tubules, thereby facilitating its excretion in urine. In the absence of drug treatment,
approximately 90% of the filtered load of glucose is reabsorbed in the proximal convoluted
tubule. Thus, SGLT2 inhibitors provide an innovative approach to reducing glycemia.
The United States (US) Food and Drug Association (FDA) has approved three drugs of
this class, including canagliflozin, dapagliflozin, and empagliflozin. As a group, SGLT2
inhibitors have excellent safety, efficacy, and tolerability profiles and present no significant risk
of hypoglycemia. In addition to improving glycemic control, SGLT2 inhibitors have numerous
positive effects on body weight, blood pressure, hyperuricemia, and dyslipidemia, and may
prevent fatty liver disease. While SGLT2 inhibitors are typically introduced as second or thirdline add-on AHAs for treating T2DM, they can also be used as first-line monotherapy when
metformin is contraindicated (Garber et al., 2020).
A systematic review by Scheen et al. (2020) concluded that the addition of an SLGT2
inhibitor to a standard metformin regimen resulted in consistent reductions in HbA1c, fasting
blood glucose, body weight, and systolic blood pressure. Of note, no significant differences were
observed between Asian and non-Asian patients.
A meta-analysis performed and reported by Chen & Li (2020) compared the efficacy of
SGLT2 inhibitors with sulfonylureas as second-line agents in patients who were not adequately
controlled on metformin alone. The authors concluded that SGLT2 inhibitors are more effective
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over the long term and do not cause hypoglycemia. Secondary outcomes in this study included
improvements in body weight and systolic blood pressure.
A systematic review by Fuchigami et al. (2020) compared the cardiovascular benefits of
drug regimens that included SLGT2 inhibitors versus those of the DPP4 class. The results of the
study suggested that SLGT2 inhibitors were superior to DPP4 inhibitors for achieving goals that
included reductions in body weight, serum aspartate transaminase (AST) and alanine
aminotransferase (ALT), fasting plasma glucose, and fasting plasma insulin levels. Consistent
with previous reports, the results of this study also suggest that the use of SGLT2 inhibitors may
improve hepatic steatosis.
A meta-analysis by Zou et al. (2020) evaluated the cardiovascular outcomes in patients
treated with SGLT2 inhibitors compared to controls. They concluded that SGLT2 inhibitors
decreased the cardiovascular risk associated with T2DM and led to a reduction in the incidence
of major adverse cardiovascular events. Usman et al. (2018) also reported that treatment with
SGLT2 inhibitors significantly reduced the incidence of major adverse cardiac events, including
non-fatal myocardial infarction, heart failure, and premature mortality in patients diagnosed with
T2DM. All three available SGLT2 inhibitors appear to have similar cardioprotective effects.
A consensus statement from the American Association of Clinical Endocrinology (2020)
confirmed that empagliflozin (Jardiance®) was associated with significantly reduced rates of allcause and cardiovascular death and reduced the risk of hospitalization for heart failure in patients
enrolled in the EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes) trial.
Lautch et al. (2020) compared the results of monotherapy and dual initiation therapy with
numerous agents. The results of their meta-analysis revealed that dual initiation therapy led to
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significantly better outcomes than were achieved with most of the monotherapy regimens with
respect to reductions in HbA1c, body weight, and SBP over 24–26 weeks of follow-up of T2DM
patients who were poorly controlled on metformin alone.
A systematic review and meta-analysis by Donnan et al. (2019) aimed to examine any
harmful post-market sequelae of SGLT2 inhibitors that were identified by drug regulatory
agencies. The authors concluded SGLT2 inhibitors were associated with no increased risk of
harm compared to placebo or active comparators, specifically with respect to acute kidney
injury, diabetic ketoacidosis, urinary tract infections, or fractures.
A randomized placebo-controlled trial conducted by Babar and Aktar (2021) compared
the outcomes of 240 obese T2DM patients with inadequate glycemic control while on both
metformin and sitagliptin (HbA1c >7%). In this 24-week study, patients in group B were
provided with add-on treatment with empagliflozin (10 mg twice a day), while patients in group
A were provided with a placebo. Patients treated with empagliflozin lost more weight than those
provided with a placebo (6.9 ± 2.4 kg versus 3.1 ± 0.8 kg, respectively).
Hussain et al. (2021) reported the results of a randomized controlled trial designed to
compare empagliflozin and dapagliflozin in patients with T2DM with inadequate glycemic
control while on conventional first-line treatment. After 12 weeks, both groups exhibited weight
loss from baseline values. Patients treated with empagliflozin exhibited a greater reduction in
body mass index (BMI) compared to the patients treated with dapagliflozin. Both drugs were
well-tolerated with no major adverse effects. Urinary tract infections were more prevalent in the
patients on dapagliflozin (9.3%) than in those treated with empagliflozin.
A randomized controlled trial performed by Hadjadj et al. (2016) compared the safety
and efficacy of combination treatment (metformin and empagliflozin together) to monotherapy
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with either metformin or empagliflozin alone in patients with T2DM. The combination of
empagliflozin and metformin was well-tolerated and resulted in significant reductions in HbA1c
compared to empagliflozin (once daily) or metformin (twice daily) alone, with no increase in the
incidence of hypoglycemia. Combination therapy also resulted in significantly greater reductions
in HbA1c than were achieved with monotherapy with either of the two drugs. The combination
regimen also resulted in a more significant weight loss at 24 weeks compared to metformin or
empagliflozin alone.
A systematic review published by Molugulu et al. (2017) reported that combined therapy
with an SGLT2 inhibitor together with metformin was more effective at promoting reductions in
body weight and HbA1c levels compared to monotherapy with metformin alone. A comparison
of the outcomes from each of the three currently-available SGLT2 inhibitors revealed no
substantial differences in weight reduction. However, empagliflozin (25 mg per day) was the
most effective at reducing HbA1c levels. SGLT2 inhibitors used in combination regimens to
treat patients with T2DM with poorly-controlled blood glucose levels were more effective at
reducing HbaA1c and body weight compared to monotherapy with metformin alone.
The final study that I reviewed was a meta-analysis that compared the effects of glucoselowering drugs on body weight and blood pressure in adults with T2DM. Metformin had a
significant impact on both body weight and systolic blood pressure. However, diastolic blood
pressure was reduced in patients treated with SGLT2 inhibitors, pioglitazone, exenatide (twice
daily), or semaglutide. In subgroup analyses of trials that lasted 52 weeks or more, semaglutide
and SGLT2 inhibitors were found to be effective at reducing both body weight and systolic
blood pressure (Tsapas et al., 2021).
Rationale
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This quality improvement (QI) project is designed to implement change in the
management of T2DM in the primary care setting using Kurt Lewin’s change model (Lewin,
1958) as shown in Figure 1. This model postulated that individuals and groups are influenced by
driving forces that can hinder, foster, or maintain change. Lewin’s theory of change comprises
three stages: Unfreezing, Change, and Refreezing. The theory explains how an intervention or set
of interventions can lead to change and allows one to promote change based on causal analysis
and best evidence.
The first phase of the change process includes efforts to “unfreeze” the current situation by
increasing the driving forces or decreasing the restraining forces that modulate change. This step
often elicits a change in the behavior of the provider. It requires an acknowledgment/awareness
that the current practice needs to be changed or abandoned. For example, Burnes (2004) stated
that feelings of discomfort, apprehension, and distress might be experienced during this period.
Educating individuals regarding the motives for change can enhance the strength of driving
forces and facilitate the transition from the first to the second stage of Lewin’s model. “Change”
(moving) is the second phase of this model. During this period, the provider moves toward a new
equilibrium of driving and restraining forces. The provider can transition to a state of
disequilibrium to change current practice treatment for T2DM, which includes the new evidencebased treatment. The final phase is “refreezing” which is a process that must occur after the
change is implemented to sustain the new equilibrium (Burnes & Bargal, 2017). In this stage, the
provider has observed the benefits of the evidence-based treatment with empagliflozin and can
refreeze and make the change permanent for patients in the future.
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Figure 1
Kurt Lewin’s Change Theory for T2DM

Change
• Current ineffective
practice identified:
Metformin 500-1000 mg
twice daily in patients
with uncontrolled
T2DM

Unfreeze

• Implement new
evidence-based
intervention:
Empagliflozin 10-25 mg
once daily with
Metformin

• Make the change
permanent

Refreeze

Specific Aims
The specific aim of this evidence-based project was to change the current ineffective
treatment for T2DM of metformin to improve my clinical practice. The evidence-based QI
intervention is the initiation of empagliflozin treatment (10–25 mg once daily) alone or as
combination therapy with metformin. The inclusion criteria were patients with uncontrolled
T2DM (HbA1c >7%) between the ages of 18-76.
Methods
Context
This evidence-based QI project was carried out at the Ben Archer Health Center, an
FQHC located in rural Las Cruces, New Mexico. There are approximately 12 clinics included
within this organization that are distributed throughout the southwest region of the state. The
project The QI project started on September 5, 2021, with CITI training for IRB human research,
HIPPA, research populations, ethical considerations, and regulations.
Intervention
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Needs assessment. On September 7, 2021, I conducted a needs assessment using a 10day reflective practice log (RPL) to identify opportunities to improve my current practice at Ben
Archer Health Center. The data that was collected in the RPL included demographics such as
age, gender, the reason for the visit, diagnosis and assessment tools used, intervention, and the
need for follow up visits. Diagnosis codes (ICD-10) and Current procedural codes (CPT) were
also included in the RPL.
Review of Patients. One-hundred-thirteen patients were recorded in the RPL. Thirty-four
different diagnoses were identified. Eleven percent were diagnosed with T2DM. Each diagnosis
was color coordinated.
Insights gained. After reviewing my ten-day RPL, I identified three potential
opportunities to improve the care that I presently provide for my patients. Three potential PICOT
questions were developed. I met with my Doctor of Nursing Practice (DNP) chairperson and
selected one PICOT question for the QI project. Once the chairperson approved my project, I
performed a literature review.
PICOT Question. This DNP QI Project aims to use evidence-based research validated
intervention to improve glycemic control in patients with uncontrolled T2DM at Ben Archer
Health Center in Las Cruces, NM.
Population: Patients 18-79 with uncontrolled T2DM (HbA1c >7%)
Intervention: Empagliflozin 10-25 mg once daily
Current practice: Metformin 500-1000 mg twice daily
Outcomes: Improved glycemic control
Time: Within 2-weeks
Literature Review
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The following question was used to guide the literature review (Figure 2):
What is the best effective evidence-based treatment for uncontrolled T2DM in adults 18-78 years
of age? I searched the literature using the CINAHL, PubMed, Embase, and Cochrane databases
for randomized-controlled trials (RCTs), clinical practice guidelines, meta-analyses, and
systematic reviews that were published in 2016 through 2021. The following keywords were
used: Type 2 Diabetes, Monotherapy, Combination therapy, Sodium-glucose cotransporter-2
inhibitor (SGLT2), and Glycemic control
Figure 2
Study Flow Diagram

Note. PRISMA 2020 flow diagram for new systematic reviews that include searches of databases
and registers only (Page et al., 2021).
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DNP QI Proposal. The Plan-Do-Study-Act (PDSA) model guided the DNP QI project (Figure
3). This tool involves a circular motion and multiple interactions in an improvement cycle. Plan
involves planning the change. Study includes analyzing results. Do is carrying out the change.
Study involves analyzing results to determine what went wrong or was learned.
Plan: Identify patients between the ages of 18–79 years with new-onset T2DM or
previously-diagnosed T2DM that remained uncontrolled on metformin (i.e., HbA1c >7%).
Initiate empagliflozin as monotherapy or as a combination treatment for patients already taking
metformin.
Do: I documented baseline HbA1c levels before initiating treatment. Patients were
scheduled for a two-week post-treatment follow-up to assess drug tolerance and HbA1c levels.
Study: I compared HbA1c levels before and after two weeks of treatment.
Act: Based on the analysis of the results of HBA1c testing, I determined the efficacy of
these drug regimens at improving blood glucose levels in patients 18-79 using an evidence-based
intervention.
Figure 3
PDSA QI for T2DM
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IRB application and work site letter approval. The QI project used evidence-based
literature and methodologies and complied fully with the federal regulations and requirements
regarding the rights and welfare of the human participants. These requirements included: A work
letter from work site manager approval letter to implement a QI project, submit QI project
proposal and application to UTEP IRB.
On November 9, 2021, UTEP IRB letter of approval was obtained for this QI project
entitled “Empagliflozin and/ or metformin: A combination approach for uncontrolled Type II
diabetes. The IRB determined this project did not meet the definition of human subject research
under the purview of the IRB according to federal regulations. On November 01, 2021, I was
granted permission by the worksite manager at Ben Archer to conduct the QI project.
Study of interventions
The QI project was performed during a six-week time frame that started on January 21,
2022. During the first four weeks, the patients were evaluated, and interventions were initiated.
The final two weeks were for follow-up. Patients who met inclusion criteria for the QI project
were between 18–78 years of age with new-onset or a known diagnosis of T2DM with an HbA1c
level >7%. I recorded the HbA1c levels at the initial visit and determined whether or not the
patient was taking metformin. I encouraged the patients to measure their fasting blood glucose
levels every morning and to bring their glucose logs to their two-week follow-up visit. The
patient was then capable of making an informed decision to accept or decline the intervention.
The patients who took part in the QI project returned to the clinic two weeks after the initiation
of the intervention. I recorded a post-intervention HbA1c level during the follow-up visit to
evaluate the efficacy of the treatment. I also recorded weight and blood pressure at each visit.
The QI project intervention incorporated the PDSA cycle consistent with its goal.
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Kurt Lewin's Model of Change (Lewin, 1958) provided the theoretical framework that
guided this QI project. This model included a three-step process (i. e., unfreezing, changing, and
refreezing). The theory explains the three-step interventions the provider must accomplish to
establish and to make the new evidence base treatment permanent
Measures
The results of my completed DNP project will have a direct impact on my patients as
they will have improved glycemic control on an evidence-based treatment with empagliflozin.
Overall, improved fasting glucose levels may also be used to monitor the improved management
of T2DM. Additional visits will provide us with the opportunity to address this and other
concerns.
Analysis
Quantitative data reflecting pre- and post-intervention HbA1c levels were collected to
determine the impact of each drug regimen. Evaluation of data is presented on one line graph for
pre and post HbA1c (figure 4). Nineteen patients (eighteen females and one male) met the
criteria for the QI project. Nine patients were < 60 years of age and 10 were >60 years of age.
Although not quantified, a pie graph (figure 5) represents the percentage of weight loss.
HbA1c measurements are a standard of care for testing and monitoring diabetes,
particularly in patients diagnosed with T2DM. The HbA1c level is an indirect measure of a
patient’s average blood glucose level over the previous two to three months (Hillson & Alberti,
2012) and is strongly correlated with fasting plasma glucose levels. HbA1c is a reliable measure
of chronic glycemia and correlates with the risk of long-term diabetes complications (John et al.,
2012). Additional qualitative data gathered at follow-up visits provided me with insight into
improved adherence and quality of life.
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Ethical Considerations
Patient Inclusion. Inclusion criteria for the QI project required adults 18-78 years of age
with uncontrolled T2DM. Patients who qualified for the QI project were consulted regarding the
decision to initiate the new treatment. I reviewed the intervention and its intended results with
each patient and also discussed the most common side effects of the medication that are currently
listed in Epocrates (https://www.epocrates.com/) and the literature. The patient was then capable
of making an informed decision to accept or decline the intervention.
Clinical data. I collected, managed, and analyzed all patient data. The patient data
remained in the electronic medical record throughout the QI project. Non-identifying data were
collected together with initial (pre-intervention baseline) and follow-up (post-intervention)
HbA1c levels.
Results
Nineteen patients met the inclusion criteria of this QI project. Eighteen were female
between the ages of 23–78 years; sixteen of these patients were Hispanic, and two were
Caucasian. The one male patient who elected to undergo treatment with empagliflozin was a
Hispanic between 40 to 50 years of age. All 19 patients who elected to undergo treatment with
empagliflozin completed the recommended follow-up visit scheduled for two weeks following
the initiation of treatment. The outcomes of this QI project are shown in Figure 4. The average
pre-intervention HbA1c level was 8.08%. The average post-intervention HbA1c level was
7.87%, representing an overall improvement of 0.21% (Figure 4).
Figure 4
Pre- and Post-Intervention HbA1c levels
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Figure 5

Note. Data from N = 19 patients.

Seventeen patients met inclusion criteria for combination empagliflozin and metformin
while only 2 patients were started on empagliflozin as a monotherapy. In the patients who were
on monotherapy, one didn’t have any improvement in HbA1c while the other exhibited a 0.3%
reduction in HbA1c at two weeks post-intervention.
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In addition to reductions in HbA1c, I observed several other secondary outcomes,
including weight loss (Figure 5), increased mental clarity, stronger motivation to manage their
T2DM, and improved satisfaction with their treatment regimens.
Interestingly, the two patients who met criteria for monotherapy with empagliflozin
exhibited more weight loss than the other seventeen patients. These two patients each lost six
pounds during the two-week interval, possibly secondary to the diuretic effect of this drug. Some
patients experienced no weight loss. However, most patients who did lose weight dropped one to
three pounds over the two-week QI project period. Many patients reported that they performed
regular glucose monitoring which helped them to remain accountable for their food choices
throughout the day. Education was also a critical component of empowering patients as part of
this QI project.
Discussion
Summary
The results of the QI project support the findings already published in the literature.
Consistent with evidence-based diabetes guidelines and recommendations, my findings suggest
that administration of empagliflozin either alone or in combination with metformin improves
glycemic control in adult patients with T2DM. Although not assessed quantitatively, the results
of my project suggest that this regimen also promotes weight reduction and reductions in systolic
blood pressure and thus provides a measure of cardioprotective and renal protective benefit to
patients with T2DM.
Interpretation
After completion of the QI project, patients who began treatment with empagliflozin
were more motivated to monitor their blood glucose levels. Most of the QI project patients
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brought their blood sugar logs to their follow-up visits and made additional dynamic behavioral
changes. Patients also reported a weight loss and a decrease in leg edema weight loss secondary
to the diuretic effect of this drug. Other reported responses included reductions in blurred vision
and considerable improvement in mental clarity. Overall, patients were satisfied with the new
medication regimen.
Limitations
The QI project was implemented at a federally qualified health center over the course of
six-weeks. The simplicity of the QI project allows for its application in other settings. However,
the sustainability of these findings will depend on whether these results can be replicated by
different providers in other clinical settings as well as overall access to and coverage provided
for this medication.
The FQHC has an on-site pharmacy that carries many new drugs, including
empagliflozin being one of them. The cost of a 90-day supply of empagliflozin either (10 mg or
25 mg tablets) has a cost of $6.88. Furthermore, the QI project was not longitudinal and thus I
was unable to assess the long-term sustainability and impact of treatment. However, information
from the literature indicates that empagliflozin continues to work well over time with no loss of
efficacy. Another limitation to this QI project was that I relied on HbA1c measurements taken
<12 weeks apart. While this was not ideal, the results clearly suggested an overall improvement
in HbA1c. Similarly, patient monitoring logs also revealed improvements in fasting blood
glucose levels over a period of 14 days.
Conclusion
The QI project aimed to improve glycemic control in patients with uncontrolled T2DM
using empagliflozin alone or together with metformin as a combination treatment. This QI

21
project showed that the use of an SGLT2 inhibitor to treat T2DM is a safe, tolerable, and
effective evidence-based option that will reduce HbA1c and fasting blood glucose levels.
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